I agree....my interpretation is IPIX is telling shareholders that the deal for B-OM will be substantial based upon their estimates for head and neck cancer in the US and Europe. As noted, that does not include the full market for other OM sufferers. I could be wrong and this only IMHO, but it sure seems like that is the underlying message.